T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MRL/lpr mice

Modifications of self antigens that occur during apoptosis might be involved in the generation of neo‐antigens, which can break tolerance and induce autoimmunity. We have previously identifiedan epitope at residues 131–151 of the U1‐70K snRNP protein, recognized by IgG antibodies and CD4+ T cells from at least two strains of lupus mice. With the aim of investigating the possible role of phosphorylation on the antigenicity of peptide 131–151 and to gain a better understanding of how this peptide can drive autoimmune response, we synthesized two peptides phosphorylated on Ser137 and 140, respectively. We show here that peptide P140 phosphorylated on Ser140 is recognized by both CD4+ T cells and antibodies from MRL/lpr mice. Furthermore, intravenous administration to lupus‐prone MRL/lpr mice of P140 in saline (but not of the non‐phosphorylated peptide) decreased proteinuria and anti‐DNA antibody production, and significantly prolonged survival of treated mice. We further demonstrated that P140 is recognized by antibodies from lupus patients and binds to various HLA DR molecules, offering new hope for manipulating T cell response in humans.

[1]  S. Muller,et al.  Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. , 2002, Arthritis and rheumatism.

[2]  R. Hoffman,et al.  Apoptotic U1-70 kd is antigenically distinct from the intact form of the U1-70-kd molecule. , 2002, Arthritis and rheumatism.

[3]  G. Steiner,et al.  Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice. , 2001, International immunology.

[4]  H. Doyle,et al.  Post-translational protein modifications in antigen recognition and autoimmunity. , 2001, Trends in immunology.

[5]  S. Muller,et al.  Key Sequences Involved in the Spreading of the Systemic Autoimmune Response to Spliceosomal Proteins , 2001, Scandinavian journal of immunology.

[6]  S. Muller,et al.  Laboratory protocols for the identification of Th cell epitopes on self-antigens in mice with systemic autoimmune diseases. , 2000, Journal of immunological methods.

[7]  Ram Raj Singh,et al.  The potential use of peptides and vaccination to treat systemic lupus erythematosus , 2000, Current opinion in rheumatology.

[8]  M. Wener,et al.  SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. , 2000, Arthritis and rheumatism.

[9]  C. Rugarli,et al.  Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. , 2000, Arthritis and rheumatism.

[10]  H. Zinger,et al.  Prevention of Systemic Lupus Erythematosus-Like Disease in (NZBxNZW)F1 Mice by Treating with CDR1- and CDR3-Based Peptides of a Pathogenic Autoantibody , 2000, Journal of Clinical Immunology.

[11]  Menotti Ruvo,et al.  Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide , 2000, Nature Biotechnology.

[12]  R. Rodenburg,et al.  Cell death: a trigger of autoimmunity? , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[13]  S. Muller,et al.  B and T cell immune response to small nuclear ribonucleoprotein particles in lupus mice: autoreactive CD4+ T cells recognize a T cell epitope located within the RNP80 motif of the 70K protein , 2000, European journal of immunology.

[14]  P. Anderson,et al.  Death, autoantigen modifications, and tolerance , 2000, Arthritis research.

[15]  A. Rosen,et al.  Cleavage by Granzyme B Is Strongly Predictive of Autoantigen Status , 1999, The Journal of experimental medicine.

[16]  L. Lu,et al.  Major peptide autoepitopes for nucleosome-specific T cells of human lupus. , 1999, The Journal of clinical investigation.

[17]  S. Datta,et al.  Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. , 1999, Journal of immunology.

[18]  J. Piette,et al.  The key role of nucleosomes in lupus. , 1999, Arthritis and rheumatism.

[19]  M. Piacentini,et al.  Tissue transglutaminase: apoptosis versus autoimmunity. , 1999, Immunology today.

[20]  P. Anderson,et al.  Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. , 1998, Arthritis and rheumatism.

[21]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[22]  P. Anderson,et al.  Association of Phosphorylated Serine/Arginine (SR) Splicing Factors With The U1–Small Ribonucleoprotein (snRNP) Autoantigen Complex Accompanies Apoptotic Cell Death , 1998, The Journal of experimental medicine.

[23]  R. Tisch,et al.  Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. , 1997, Immunology today.

[24]  C. Leclerc,et al.  In vivo T helper cell response to retro-inverso peptidomimetics. , 1997, Journal of immunology.

[25]  F. Sinigaglia,et al.  Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. , 1997, Journal of immunology.

[26]  P. Schur,et al.  Proteins Phosphorylated during Stress-induced Apoptosis Are Common Targets for Autoantibody Production in Patients with Systemic Lupus Erythematosus , 1997, The Journal of experimental medicine.

[27]  P. Allen,et al.  Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands , 1996, The Journal of experimental medicine.

[28]  J. Berden,et al.  Dual Reactivity of Several Monoclonal Anti-nucleosome Autoantibodies for Double-stranded DNA and a Short Segment of Histone H3* , 1996, The Journal of Biological Chemistry.

[29]  M. Davis,et al.  Altered T cell receptor ligands trigger a subset of early T cell signals. , 1996, Immunity.

[30]  E. Tan,et al.  Recent developments in the understanding of antinuclear autoantibodies. , 1996, International archives of allergy and immunology.

[31]  P. Allen,et al.  Essential flexibility in the T-cell recognition of antigen , 1996, Nature.

[32]  E. Sercarz,et al.  Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. , 1995, The Journal of clinical investigation.

[33]  L. Samelson,et al.  Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists , 1995, Science.

[34]  Z. Nagy,et al.  Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning , 1994, The Journal of experimental medicine.

[35]  C. Janeway,et al.  Both high and low avidity antibodies to the T cell receptor can have agonist or antagonist activity. , 1994, Immunity.

[36]  S. Kusumoto,et al.  An Efficient Procedure for Solid-Phase Synthesis of Phosphopeptides by the Fmoc Strategy , 1994 .

[37]  A. Rosen,et al.  Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes , 1994, The Journal of experimental medicine.

[38]  P. Allen,et al.  Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Briand,et al.  Development of a fully automated multichannel peptide synthesizer with integrated TFA cleavage capability. , 1993, Peptide research.

[40]  C. Will,et al.  Identification of an snRNP-associated kinase activity that phosphorylates arginine/serine rich domains typical of splicing factors. , 1993, Nucleic acids research.

[41]  J. Tazi,et al.  Thiophosphorylation of U1-70K protein inhibits pre-mRNA splicing , 1993, Nature.

[42]  R. Germain,et al.  Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling , 1993, The Journal of experimental medicine.

[43]  H. Grey,et al.  Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on T-cell signaling events. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Grey,et al.  Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor , 1992, Cell.

[45]  R. Lührmann,et al.  Characterisation of human and murine snRNP proteins by two-dimensional gel electrophoresis and phosphopeptide analysis of U1-specific 70K protein variants. , 1990, Nucleic acids research.

[46]  J. Harley,et al.  A MODEL FOR DISEASE HETEROGENEITY IN SYSTEMIC LUPUS ERYTHEMATOSUS: Relationships Between Histocompatibility Antigens, Autoantibodies, and Lymphopenia or Renal Disease , 1989, Arthritis and rheumatism.

[47]  A. Steinberg,et al.  HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens. , 1987, Annals of the rheumatic diseases.

[48]  K. Elkon,et al.  Apoptosis in rheumatic diseases. , 2000, The American journal of medicine.

[49]  J. Levine,et al.  The role of apoptosis in autoimmunity: immunogen, antigen, and accelerant. , 1999, Seminars in nephrology.

[50]  D. Isenberg,et al.  Apoptosis in human autoimmune diseases. , 1999, International reviews of immunology.

[51]  A. Rosen,et al.  Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease , 1999, Cell Death and Differentiation.

[52]  M. Bevan,et al.  T cell receptor antagonists and partial agonists. , 1995, Immunity.